Pancreatectomía posneoadyuvancia en cáncer resecable "borderline" / Pancreatectomy after neoadjuvant therapy in borderline resectable pancreatic cancer

RESUMEN Antecedentes: la pancreatectomía posneoadyuvancia en paciente sin progresión de la enfermedad es el tratamiento estándar en el cáncer pancreático "borderline"; sin embargo, no existe hasta ahora ninguna serie nacional publicada. Objetivo: evaluar la morbilidad y mortalidad de la pancreatectomía en pacientes con cáncer de páncreas resecable "borderline" tratados previamente con neoadyuvancia. Material y métodos: se analizaron 15 pacientes tratados en el período 2011-2018. Se evaluaron los datos epidemiológicos, el tipo de neoadyuvancia, la respuesta radiológica posneoadyuvancia, la morbilidad, mortalidad y supervivencia. Se compararon los 15 pacientes pancretectomizados posneoadyuvancia con 15 pacientes pancreatectomizados sin neoadyuvancia previa. Resultados: de los 15 pacientes, 8 eran del sexo masculino y el promedio de edad fue de 66,5 años. El tipo de neoadyuvancia más frecuente fue folforinox (n = 6) y gemcitabina/placitaxel (n = 5); se adicionó radioterapia en 8 pacientes. La evaluación radiológica posneoadyuvancia mostró enfermedad estable en 10 pacientes y respuesta parcial en 4. Se realizaron 11 duodenopancreatectomías y 4 esplenopancreatectomías. En 10 pacientes fue necesario algún tipo de resección vascular. La morbilidad fue del 60% (9/6), no se registró mortalidad y la supervivencia media fue de 23,4 meses. No hubo diferencias significativas en la morbilidad, mortalidad y supervivencia cuando se comparó con los 15 pacientes pancreatectomizados sin neaodyuvancia. Conclusión: el tratamiento con neoadyuvancia en cáncer de páncreas avanzado permite ampliar su resecabilidad. La pancreatectomía posneoadyuvancia, en centros de alto volumen, tiene morbilidad, mortalidad y supervivencia similares a las de las pancreatectomías que no requieren neaoadyuvancia.

ABSTRACT Background: Pancreatectomy after neoadjuvant therapy in patients without disease progression is the standard treatment for borderline pancreatic cancer; however, no national series have been published to date. Objective: The aim of this study is to evaluate morbidity and mortality of patients with borderline resectable pancreatic cancer undergoing pancreatectomy after neoadjuvant therapy. Material and methods: A total of 15 patients treated between 2011 and 2018 were analyzed. The epidemiologic data, type of neodajuvant therapy, radiological evaluation of the response to neoadjuvant therapy, morbidity, mortality and survival were evaluated. These 15 patients who underwent pancreatectomy after neoadjuvant therapy were compared with 15 pancreatectomized patients without previous neoadjuvant therapy. Results: Mean age was 66.5 years and 8 patients were men. The most common neoadjuvant therapy regimens were FOLFIRINOX (n = 6) and gemcitabine/paclitaxel (n = 5); 8 patients required additional radiation therapy. The radiological evaluation of the response to neoadjuvant therapy showed stable disease in 10 patients and partial response in 4. Eleven patients underwent pancreaticoduodenectomy and 4 underwent splenectomy and pancreatectomy. Ten patients required some type of vascular resection. Morbidity was 60% (9/15), there were no deaths and mean survival was 23.4 months. There were no significant differences in morbidity, mortality and survival with the 15 pancreatectomized patients without previous neoadjuvant therapy. Conclusion: Neoadjuvant therapy has extended resectability of advanced pancreatic cancer. In high volume centers, pancreatectomy after neoadjuvant therapy has similar morbidity, and survival to those of pancreatic resections without previous neoadjuvant therapy.

A Multimodal Approach for the First-Line Treatment of Infected Pancreatic Necrosis.

OBJECTIVES: Because infected pancreatic necrosis (IPN) has multiple presentations, not all patients are likely to benefit from the same first-line treatment. Our objective was to evaluate morbidity and mortality in a series of patients treated with a multimodal therapeutic approach. METHODS: Between May 2012 and May 2019, 51 patients diagnosed with IPN were treated. The 5 initial treatment alternatives were as follows: percutaneous drainage, minimally invasive necrosectomy, antibiotics alone, transgastric necrosectomy, and temporizing percutaneous/endoscopic drainage. Initial treatment selection depended on evolution, clinical condition, and extension of pancreatic necrosis. Success, morbidity, and mortality rates were determined. RESULTS: In terms of determinant-based classification, 37 were classified as severe, and 14 as critical. Percutaneous, temporizing drainage, minimally invasive necrosectomy, antibiotics alone and transgastric necrosectomy approaches were used in 21, 10, 11, 4, and 5 patients, respectively. Necrosectomy was not required in 18 patients (35%). There were no significant differences in mortality among the different treatment approaches (P < 0.45). Overall success, morbidity, and mortality rates were 68.6%, 52.9%, and 7.8%, respectively. CONCLUSIONS: The multimodal approach seems to be a rational and efficient strategy for the initial treatment of IPN.

Impacto de la pandemia COVID-19 en la cirugía pancreática. Análisis en dos instituciones, una pública y otra privada / Impact of the COVID-19 pandemic on pancreatic surgery. Analysis in a public and a private institution

RESUMEN Antecedentes: la pandemia de COVID-19 ha introducido cambios drásticos en el sistema de salud. Las cirugías electivas son una de las actividades quirúrgicas que más han descendido durante la pandemia. Objetivo: analizar el impacto de la pandemia de COVID-19 en la cirugía pancreática en una institución pública y otra privada. Se comparó, en cada institución, con el número de cirugías en el mismo período del año pasado. Material y métodos: se revisaron en una base prospectiva los pacientes que recibieron una cirugía pancreática en las dos instituciones entre el 10/3/20 y el 24/6/20. Se determinaron los datos epide miológicos, el tipo de resección pancreática, el diagnóstico anatomopatológico, la morbilidad y la mor talidad. Se compararon con los pacientes en ambas instituciones que recibieron cirugía pancreática durante el período 10/3/19 al 24/6/19. Resultados: durante la pandemia se realizaron 23 resecciones pancreáticas (13 duodenopancreatec tomías cefálicas, 9 pancreatectomías izquierdas y 1 pancreatectomía total). El 70% (16/23) fueron adenocarcinomas. La morbilidad alcanzó el 34,7% y no se registró mortalidad. Ningún paciente ni miembro del equipo quirúrgico se infectó con coronavirus. La pandemia no tuvo impacto en el núme ro de cirugías en el centro privado (22 vs. 20, p = 0,88), mientras que en el centro público hubo una reducción significativa en el número de cirugías (14 vs. 3, p = 0,009). Conclusión: la cirugía pancreática se puede hacer con seguridad durante la pandemia. En el centro privado se mantuvo el número de cirugías pancreáticas. En el centro público, con máxima prioridad para pacientes con COVID-19, hubo un descenso significativo.

ABSTRACT Background: The COVID-19 pandemic has introduced dramatic changes in the health system. Elective surgeries are the surgical activities with greater decline during the pandemic. Objective: The aim of this paper is to analyze the impact of the COVID-19 pandemic in pancreatic sur gery in a public and a private institution. The number of surgeries performed in each institution was compared with those performed in same period of the previous year. Material and methods: Data from a prospective database of all the patients who underwent pancrea tic surgery between March 10, 2020, and June 3, 2020, were analyzed. The epidemiological data, type of pancreatic resection, pathology diagnosis, morbidity and mortality were determined in each insti tution and compared with patients who underwent pancreatic surgery in both institutions between March 3, 2019, and June 24, 2019. Results: 23 pancreatic resections were performed during the pandemic (13 cephalic pancreaticoduo denectomies, 9 left pancreatectomies and 1 total pancreatectomy); 70% (16/23) were adenocarcino mas. There were 34.7% complications and no deaths were reported. None of the patients was infected with coronavirus. The pandemic had no impact on the number of pancreatic resections in the private institution (22 vs. 20, p = 0.88), while the number of pancreatic surgeries was significantly lower in the public center (14 vs. 3, p = 0.009). Conclusion: Pancreatic surgery can be safely performed during the pandemic. The number of pancrea tic surgeries did not decline during the pandemic. The priority for treating patients with COVID-19 at the public center resulted in a significant decrease in pancreatic surgeries.